Key result
Higher GRACE score is linked to ~31% higher 1-year mortality per 10 points.
Why the study?
Does the prognostic performance and discrimination of the GRACE risk score for mortality vary by the extent of baseline coronary artery disease in STEMI patients?
Cohort (n=1,099)
No
Does the prognostic performance and discrimination of the GRACE risk score for mortality vary by the extent of baseline coronary artery disease in STEMI patients?
Hazard Ratio: 1.31 (95% CI 1.16–1.47)
p-value: p=<0.001
The prognostic accuracy of the GRACE risk score in STEMI is significantly modified by the anatomical extent of coronary artery disease, performing well in single-vessel disease but losing discriminative ability in patients with severe multivessel disease.
No takes yet. Share an insight, caveat, or question.
Caution advised applying GRACE in multivessel STEMI; leaves open whether CAD extent should modify its use in risk models.
BACKGROUND: The GRACE (Global Registry of Acute Coronary Events) score is well validated for risk stratification in non-ST-segment-elevation myocardial infarction, but less well established in ST-segment-elevation myocardial infarction (STEMI), particularly relative to coronary disease burden. We therefore assessed its prognostic performance in a STEMI cohort, accounting for baseline coronary disease extent. METHODS: We studied 1099 patients with STEMI from the CardioLines Coronary Biobank (2015-2021) with evaluable GRACE score and follow-up data. Patients were stratified by the number of coronary vessels with significant stenosis. The primary end point was all-cause death at 1 year; the secondary end point was a combined end point, including all-cause death, recurrent acute coronary syndrome, stroke, and revascularization at 1 year. In multivariable models, each 10-point increase in GRACE score was associated with a 31% higher risk of all-cause death and a 14% higher risk of the combined end point at 1 year. In single-vessel disease, discrimination for all-cause death was excellent early (30-day area under the curve, 0.874 [95% CI, 0.755-0.991]) and moderate at 1 year (area under the curve, 0.77 [95% CI, 0.613-0.927]), but consistently poor in 3-vessel disease (area under the curve, 0.52-0.57). Discrimination was significantly higher in single- versus multivessel disease at earlier time points, with differences attenuated by 1 year. Stratified regression analyses confirmed stronger associations in single-vessel versus multivessel disease. CONCLUSIONS: In this contemporary STEMI cohort, the GRACE score effectively stratifies event risk in single-vessel but performs poorly in multivessel disease. These findings suggest variable prognostic utility of the GRACE score across anatomic disease burden post-STEMI and caution when applying it across STEMI subgroups.
Kuku et al. (2026) conducted a cohort in ST-segment-elevation myocardial infarction (STEMI) (n=1,099). GRACE score (per 10-point increase) was evaluated on All-cause death at 1 year (HR 1.31, 95% CI 1.16-1.47, p=<0.001). Each 10-point increase in the GRACE score was associated with a 31% higher risk of all-cause death at 1 year (HR 1.31), though its discriminative performance declined significantly in multivessel disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: